Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 1.00 |
| ▸ | JAK1 | P23458 | 19/20 | 1.00 |
| ▸ | JAK3 | P52333 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | SYK | P43405 | 1/20 | 0.68 |
| ▸ | TYK2 | P29597 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378236 | 0.84 | JAK3 (0.73) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2377096 | 0.82 | JAK2 (0.70) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2378235 | 0.82 | JAK1 (0.70) | JAK2JAK1JAK3CYP2C9SYK | |
| SCHEMBL2378535 | 0.82 | JAK2 (0.70) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2280040 | 0.82 | SYK (1.00) | JAK2JAK1JAK3CYP2C9SYK | |
| SCHEMBL2380310 | 0.81 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2378523 | 0.81 | JAK2 (0.68) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2379596 | 0.81 | JAK1 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL14751526 | 0.80 | JAK2 (1.00) | JAK2JAK1JAK3SYKTYK2 | |
| SCHEMBL2379061 | 0.80 | JAK2 (0.67) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | claimed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | JAK2 5/4885JAK1 6/4885JAK3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.